Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones.

Isabel E, Aspiotis R, Black WC, Colucci J, Fortin R, Giroux A, Grimm EL, Han Y, Mellon C, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Tawa P, Vaillancourt JP, Xanthoudakis S, Zamboni RJ.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1671-4. Epub 2007 Jan 11.

PMID:
17251019
2.

Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive neurons in Alzheimer's disease.

Ayala-Grosso C, Tam J, Roy S, Xanthoudakis S, Da Costa D, Nicholson DW, Robertson GS.

Neuroscience. 2006 Aug 25;141(2):863-874. doi: 10.1016/j.neuroscience.2006.04.041. Epub 2006 Jun 5.

PMID:
16750894
3.

Correlating the fractional inhibition of caspase-3 in NT2 cells with apoptotic markers using an active-caspase-3 enzyme-linked immunosorbent assay.

Tawa P, Giroux A, Grimm E, Han Y, Nicholson DW, Xanthoudakis S.

Anal Biochem. 2006 Mar 1;350(1):32-40. Epub 2005 Dec 21.

PMID:
16430849
4.

Lipophilic versus hydrogen-bonding effect in P3 on potency and selectivity of valine aspartyl ketones as caspase 3 inhibitors.

Mellon C, Aspiotis R, Black CW, Bayly CI, Grimm EL, Giroux A, Han Y, Isabel E, McKay DJ, Nicholson DW, Rasper DM, Roy S, Tam J, Thornberry NA, Vaillancourt JP, Xanthoudakis S, Zamboni R.

Bioorg Med Chem Lett. 2005 Sep 1;15(17):3886-90.

PMID:
16023344
5.

Gob-5 is not essential for mucus overproduction in preclinical murine models of allergic asthma.

Robichaud A, Tuck SA, Kargman S, Tam J, Wong E, Abramovitz M, Mortimer JR, Burston HE, Masson P, Hirota J, Slipetz D, Kennedy B, O'Neill G, Xanthoudakis S.

Am J Respir Cell Mol Biol. 2005 Sep;33(3):303-14. Epub 2005 Jun 9. Erratum in: Am J Respir Cell Mol Biol. 2006 Mar;34(3):383. Mortimer, James [corrected to Mortimer, James R].

PMID:
15947424
6.

Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.

Han Y, Giroux A, Colucci J, Bayly CI, Mckay DJ, Roy S, Xanthoudakis S, Vaillancourt J, Rasper DM, Tam J, Tawa P, Nicholson DW, Zamboni RJ.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.

PMID:
15686936
7.

Effects of fimbria-fornix transection on calpain and choline acetyl transferase activities in the septohippocampal pathway.

Ayala-Grosso C, Tam J, Xanthoudakis S, Bureau Y, Roy S, Nicholson DW, Robertson GS.

Neuroscience. 2004;126(4):927-40.

PMID:
15207327
8.

Solid phase synthesis of selective caspase-3 peptide inhibitors.

Grimm EL, Roy B, Aspiotis R, Bayly CI, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Tawa P, Vaillancourt JP, Xanthoudakis S, Zamboni RJ.

Bioorg Med Chem. 2004 Mar 1;12(5):845-51.

PMID:
14980595
9.

Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease.

Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, O'Donnell R, Tam J, Han Y, Colucci J, Giroux A, Zhu Y, Boucher M, Pikounis B, Xanthoudakis S, Roy S, Rigby M, Zamboni R, Robertson GS, Ng GY, Nicholson DW, Flückiger JP.

Br J Pharmacol. 2004 Feb;141(4):689-97. Epub 2004 Jan 26.

10.

Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors.

Han Y, Giroux A, Grimm EL, Aspiotis R, Francoeur S, Bayly CI, Mckay DJ, Roy S, Xanthoudakis S, Vaillancourt JP, Rasper DM, Tam J, Tawa P, Thornberry NA, Paterson EP, Garcia-Calvo M, Becker JW, Rotonda J, Nicholson DW, Zamboni RJ.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):805-8.

PMID:
14741294
11.

Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics.

Méthot N, Huang J, Coulombe N, Vaillancourt JP, Rasper D, Tam J, Han Y, Colucci J, Zamboni R, Xanthoudakis S, Toulmond S, Nicholson DW, Roy S.

J Exp Med. 2004 Jan 19;199(2):199-207. Epub 2004 Jan 12.

12.

Catalytic activity of caspase-3 is required for its degradation: stabilization of the active complex by synthetic inhibitors.

Tawa P, Hell K, Giroux A, Grimm E, Han Y, Nicholson DW, Xanthoudakis S.

Cell Death Differ. 2004 Apr;11(4):439-47.

13.

Nicotinyl aspartyl ketones as inhibitors of caspase-3.

Isabel E, Black WC, Bayly CI, Grimm EL, Janes MK, McKay DJ, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Thornberry NA, Vaillancourt JP, Xanthoudakis S, Zamboni R.

Bioorg Med Chem Lett. 2003 Jul 7;13(13):2137-40.

PMID:
12798321
14.

Immunohistochemical and biochemical assessment of caspase-3 activation and DNA fragmentation following transient focal ischemia in the rat.

Davoli MA, Fourtounis J, Tam J, Xanthoudakis S, Nicholson D, Robertson GS, Ng GY, Xu D.

Neuroscience. 2002;115(1):125-36.

PMID:
12401327
15.
16.

Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis.

Schwab BL, Guerini D, Didszun C, Bano D, Ferrando-May E, Fava E, Tam J, Xu D, Xanthoudakis S, Nicholson DW, Carafoli E, Nicotera P.

Cell Death Differ. 2002 Aug;9(8):818-31.

17.

Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury.

Han BH, Xu D, Choi J, Han Y, Xanthoudakis S, Roy S, Tam J, Vaillancourt J, Colucci J, Siman R, Giroux A, Robertson GS, Zamboni R, Nicholson DW, Holtzman DM.

J Biol Chem. 2002 Aug 16;277(33):30128-36. Epub 2002 Jun 10.

18.

Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons.

Bilsland J, Roy S, Xanthoudakis S, Nicholson DW, Han Y, Grimm E, Hefti F, Harper SJ.

J Neurosci. 2002 Apr 1;22(7):2637-49.

19.

Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi.

Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, Hackam AS, Tam J, Vaillancourt JP, Houtzager V, Rasper DM, Roy S, Hayden MR, Nicholson DW.

Nat Cell Biol. 2002 Feb;4(2):95-105.

PMID:
11788820
20.

Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia.

Back SA, Han BH, Luo NL, Chricton CA, Xanthoudakis S, Tam J, Arvin KL, Holtzman DM.

J Neurosci. 2002 Jan 15;22(2):455-63.

21.

Quantitative analysis of fluorescent caspase substrate cleavage in intact cells and identification of novel inhibitors of apoptosis.

Tawa P, Tam J, Cassady R, Nicholson DW, Xanthoudakis S.

Cell Death Differ. 2001 Jan;8(1):30-7.

22.

Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte.

Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE.

Nat Immunol. 2000 Dec;1(6):496-501.

PMID:
11101871
23.

Heat-shock proteins as death determinants.

Xanthoudakis S, Nicholson DW.

Nat Cell Biol. 2000 Sep;2(9):E163-5. Review. No abstract available.

PMID:
10980714
24.

Caspase-3-dependent neuronal death in the hippocampus following kainic acid treatment.

Faherty CJ, Xanthoudakis S, Smeyne RJ.

Brain Res Mol Brain Res. 1999 Jun 18;70(1):159-63.

PMID:
10381555
25.

Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation.

Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW.

Cell. 1999 Apr 30;97(3):395-406.

26.

Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis.

Xanthoudakis S, Roy S, Rasper D, Hennessey T, Aubin Y, Cassady R, Tawa P, Ruel R, Rosen A, Nicholson DW.

EMBO J. 1999 Apr 15;18(8):2049-56.

27.

Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex.

Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, MacPherson DP, Black SC, Hornung F, Lenardo MJ, Hayden MR, Roy S, Nicholson DW.

Cell Death Differ. 1998 Apr;5(4):271-88.

28.

Identification of redox/repair protein Ref-1 as a potent activator of p53.

Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C.

Genes Dev. 1997 Mar 1;11(5):558-70.

29.

The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice.

Xanthoudakis S, Smeyne RJ, Wallace JD, Curran T.

Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):8919-23.

30.

An enhanced immune response in mice lacking the transcription factor NFAT1.

Xanthoudakis S, Viola JP, Shaw KT, Luo C, Wallace JD, Bozza PT, Luk DC, Curran T, Rao A.

Science. 1996 May 10;272(5263):892-5. Erratum in: Science 1996 Sep 6;273(5280):1325.

PMID:
8629027
31.

Redox regulation of AP-1: a link between transcription factor signaling and DNA repair.

Xanthoudakis S, Curran T.

Adv Exp Med Biol. 1996;387:69-75. Review. No abstract available.

PMID:
8794196
32.

A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium.

Okazaki T, Chung U, Nishishita T, Ebisu S, Usuda S, Mishiro S, Xanthoudakis S, Igarashi T, Ogata E.

J Biol Chem. 1994 Nov 11;269(45):27855-62.

33.

Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia.

Yao KS, Xanthoudakis S, Curran T, O'Dwyer PJ.

Mol Cell Biol. 1994 Sep;14(9):5997-6003.

34.

The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains.

Xanthoudakis S, Miao GG, Curran T.

Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):23-7.

35.

Analysis of c-Fos and c-Jun redox-dependent DNA binding activity.

Xanthoudakis S, Curran T.

Methods Enzymol. 1994;234:163-74. No abstract available.

PMID:
7808290
36.

Escape from redox regulation enhances the transforming activity of Fos.

Okuno H, Akahori A, Sato H, Xanthoudakis S, Curran T, Iba H.

Oncogene. 1993 Mar;8(3):695-701.

PMID:
8437852
37.

The regulation of c-fos: too much is never enough.

Curran T, Abate C, Baker S, Kerppola T, Xanthoudakis S.

Adv Second Messenger Phosphoprotein Res. 1993;28:271-7. Review. No abstract available.

PMID:
8398414
38.

Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme.

Xanthoudakis S, Miao G, Wang F, Pan YC, Curran T.

EMBO J. 1992 Sep;11(9):3323-35.

40.

UV cross-linking of distinct proteins to the PRDII domain of the interferon-beta promoter.

Xanthoudakis S, Hiscott J.

Biochem Biophys Res Commun. 1990 Mar 30;167(3):1086-93.

PMID:
2157423
41.
42.

Multiple protein-DNA interactions within the human interferon-beta regulatory element.

Xanthoudakis S, Cohen L, Hiscott J.

J Biol Chem. 1989 Jan 15;264(2):1139-45.

43.

Modulation of interferon gene transcription by positive and negative cellular factors.

Xanthoudakis S, Hiscott J.

Biochem Biophys Res Commun. 1988 Aug 15;154(3):1338-44.

PMID:
3408502
44.

trans activation of type 1 interferon promoters by simian virus 40 T antigen.

Hiscott J, Wong A, Alper D, Xanthoudakis S.

Mol Cell Biol. 1988 Aug;8(8):3397-405.

45.

Transient expression of the beta interferon promoter in human cells.

Xanthoudakis S, Alper D, Hiscott J.

Mol Cell Biol. 1987 Oct;7(10):3830-5.

46.

Supplemental Content

Loading ...
Support Center